Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/LARP4B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/LARP4B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/LARP4B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/LARP4B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LARP4B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LARP4B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/LARP4B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LARP4B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/LARP4B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/LARP4B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LARP4B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00457274 | Colorectum | FAP | positive regulation of translation | 34/2622 | 136/18723 | 4.43e-04 | 5.25e-03 | 34 |
GO:19023733 | Colorectum | FAP | negative regulation of mRNA catabolic process | 19/2622 | 63/18723 | 7.22e-04 | 7.72e-03 | 19 |
GO:00482553 | Colorectum | FAP | mRNA stabilization | 17/2622 | 56/18723 | 1.24e-03 | 1.16e-02 | 17 |
GO:19033115 | Colorectum | CRC | regulation of mRNA metabolic process | 80/2078 | 288/18723 | 3.21e-15 | 6.40e-12 | 80 |
GO:00098955 | Colorectum | CRC | negative regulation of catabolic process | 75/2078 | 320/18723 | 2.02e-10 | 9.31e-08 | 75 |
GO:00064025 | Colorectum | CRC | mRNA catabolic process | 58/2078 | 232/18723 | 1.77e-09 | 5.31e-07 | 58 |
GO:00610135 | Colorectum | CRC | regulation of mRNA catabolic process | 45/2078 | 166/18723 | 8.14e-09 | 1.85e-06 | 45 |
GO:00313305 | Colorectum | CRC | negative regulation of cellular catabolic process | 61/2078 | 262/18723 | 1.27e-08 | 2.54e-06 | 61 |
GO:00064015 | Colorectum | CRC | RNA catabolic process | 63/2078 | 278/18723 | 2.21e-08 | 3.23e-06 | 63 |
GO:00434885 | Colorectum | CRC | regulation of mRNA stability | 40/2078 | 158/18723 | 3.96e-07 | 3.21e-05 | 40 |
GO:00434875 | Colorectum | CRC | regulation of RNA stability | 41/2078 | 170/18723 | 1.13e-06 | 6.69e-05 | 41 |
GO:00064175 | Colorectum | CRC | regulation of translation | 82/2078 | 468/18723 | 1.79e-05 | 5.40e-04 | 82 |
GO:00346555 | Colorectum | CRC | nucleobase-containing compound catabolic process | 73/2078 | 407/18723 | 2.28e-05 | 6.57e-04 | 73 |
GO:00442705 | Colorectum | CRC | cellular nitrogen compound catabolic process | 78/2078 | 451/18723 | 4.48e-05 | 1.07e-03 | 78 |
GO:00467005 | Colorectum | CRC | heterocycle catabolic process | 77/2078 | 445/18723 | 4.92e-05 | 1.14e-03 | 77 |
GO:19033125 | Colorectum | CRC | negative regulation of mRNA metabolic process | 23/2078 | 92/18723 | 1.36e-04 | 2.56e-03 | 23 |
GO:19023694 | Colorectum | CRC | negative regulation of RNA catabolic process | 20/2078 | 75/18723 | 1.42e-04 | 2.62e-03 | 20 |
GO:00194395 | Colorectum | CRC | aromatic compound catabolic process | 77/2078 | 467/18723 | 2.42e-04 | 4.00e-03 | 77 |
GO:19013615 | Colorectum | CRC | organic cyclic compound catabolic process | 80/2078 | 495/18723 | 3.52e-04 | 5.34e-03 | 80 |
GO:19023734 | Colorectum | CRC | negative regulation of mRNA catabolic process | 17/2078 | 63/18723 | 3.75e-04 | 5.57e-03 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LARP4B | SNV | Missense_Mutation | | c.1148G>T | p.Gly383Val | p.G383V | Q92615 | protein_coding | deleterious(0.01) | benign(0.231) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
LARP4B | SNV | Missense_Mutation | novel | c.792N>G | p.Phe264Leu | p.F264L | Q92615 | protein_coding | deleterious(0.05) | probably_damaging(0.997) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
LARP4B | SNV | Missense_Mutation | | c.895T>C | p.Phe299Leu | p.F299L | Q92615 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E2-A154-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
LARP4B | SNV | Missense_Mutation | | c.1285C>G | p.Pro429Ala | p.P429A | Q92615 | protein_coding | tolerated(0.44) | benign(0.001) | TCGA-EW-A1OY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
LARP4B | deletion | Frame_Shift_Del | novel | c.793delN | p.Ile265Ter | p.I265* | Q92615 | protein_coding | | | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
LARP4B | insertion | Frame_Shift_Ins | novel | c.614_615insATCAC | p.Asp206SerfsTer6 | p.D206Sfs*6 | Q92615 | protein_coding | | | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
LARP4B | SNV | Missense_Mutation | novel | c.100N>G | p.Gln34Glu | p.Q34E | Q92615 | protein_coding | tolerated_low_confidence(0.32) | benign(0) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
LARP4B | SNV | Missense_Mutation | | c.817N>A | p.Asp273Asn | p.D273N | Q92615 | protein_coding | tolerated(0.31) | probably_damaging(1) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LARP4B | SNV | Missense_Mutation | | c.532T>C | p.Tyr178His | p.Y178H | Q92615 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LARP4B | SNV | Missense_Mutation | rs199947494 | c.2174N>A | p.Arg725His | p.R725H | Q92615 | protein_coding | deleterious(0.03) | benign(0.01) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |